secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001493152-24-038590
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma enters two service agreements: $615K cash + 50K RSUs
------------------------------------------------------------------

- CEO.CA Technologies to provide advertising and consulting for $250,000 over 12 months.
- Belair Capital Advisors to provide strategic advisory for $365,000 plus 50,000 RSUs vesting in 6 months.
- Services include digital marketing, market research, business development assistance, and stakeholder communication.
- Both agreements are governed by Ontario law and contain standard indemnification clauses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224038590/0001493152-24-038590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224038590/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-038590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer